Skip to main content

Table 1 Association between SNCG expression and clinicopathologic characteristics of patients with prostate cancer

From: Neural protein gamma-synuclein interacting with androgen receptor promotes human prostate cancer progression

  SNCG NO. samples P
  - + ++ +++   
Prostatitis tissues 10 0 0 0 10 <0.001
BPH tissues 8 0 2 0 10 <0.001
Prostate cancer tissues (androgen-independent) 5 0 0 0 5 <0.001
Prostate cancer tissues (androgen-dependent) 48 24 31 19 122  
PSA <10 22(57.9%) 9(23.7%) 6(15.8%) 1(3.6%) 38 0.004
  ≥10 26(31.0%) 15(17.9%) 25(29.8%) 18(21.3%) 84  
Gleason score ≤6 19(59.3%) 6(18.8%) 5(15.6%) 2(6.3%) 32 0.037
  ≥7 29(32.2%) 18(20.0%) 26(28.9%) 17(18.9%) 90  
Clinical stage ≤T2a 13(52.0%) 7(28.0%) 3(12.0%) 2(8.0%) 25 0.042
  ≥T2b 35(36.1%) 17(17.5%) 28(28.9%) 17(17.5%) 97  
Lymph node invasion Negative 46(42.2%) 24(22.0%) 28(25.7%) 11(10.1%) 109 <0.001
  positive 2(15.4%) 0 3(23.1%) 8(61.5%) 13  
AR - 19(44.2%) 8(18.6%) 10(23.3%) 6(13.9%) 43 0.881
  + 29(36.7%) 16(20.3%) 21(26.6%) 13(16.4%) 79